Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

In a deal worth around $600m, Rohto Pharmaceutical is poised to expand its dietary supplements offering in Southeast Asia through the acquisition of a controlling stake in Singapore's Eu Yan Sang.

Sweden's Karo has struck its second deal in six months bringing in the Proctosedyl hemorrhoid brand from Bayer.

Sanofi CHC sales up 9% in Q1 driven by addition of US healthy aging supplement brand Qunol. Separately, the Paris-based firm has reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in the US.

At-home fertility-related hormone test developer Proov sells equity stake to entertainers and expectant parents Ashanti and Nelly; sexual and vaginal health product firm Good Clean Love moves from its founder as leader to a consumer health industry executive.

R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.

Sanofi CHC sales up 9% in Q1 driven by addition of US healthy aging supplement brand Qunol. Separately, the Paris-based firm has reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in the US.

R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

J&J, Target and Walgreens face class action complaints in California federal courts for economic harms caused by their sale of benzoyl peroxide-containing acne treatments, following Valisure’s 5 March citizen petition to the US FDA on findings of high levels of benzene in such products.

Habitually noncompliant companies are laughing at FDA, Peter Barton Hutt says.